5 citations
,
January 2021 in “IEEE Access” In this study, researchers demonstrated that treating platelet rich plasma with microsecond pulsed electric fields effectively activates platelets and induces similar or higher growth factor release compared to traditional bovine thrombin, suggesting a potential clinical use that may be more cost-effective and practical.
7 citations
,
December 2016 in “Journal of The Taiwan Institute of Chemical Engineers” This study found that porcine platelet-rich plasma can be a commercially viable replacement for fetal bovine serum with similar effectiveness in promoting human hair follicle cell growth.
February 2017 in “Spectrum Research Repository (Concordia University)” This study confirmed porcine PRP's commercial viability as a fetal bovine serum replacement, showing higher growth factor levels and stability, without increasing human follicle dermal papilla cell proliferation compared to FBS.
July 2023 in “BENTHAM SCIENCE PUBLISHERS eBooks” This book chapter reviews the subclasses and applications of platelet-rich plasma in tissue engineering and highlights the challenges in clinical translation without reporting new clinical results.
3 citations
,
April 2021 in “PLoS ONE” The authors concluded that controlling voltage, pulse width, and calcium concentration in pulse electric field-activated platelet-rich plasma enhances the release of growth factors and serotonin without causing clot formation, suggesting potential clinical advantages over bovine thrombin-activated PRP.